Skip to main content Skip to search
Yoga for the Management of Cancer Treatment-Related Toxicities
Current oncology reports
Short Title: Curr.Oncol.Rep.
Format: Journal Article
Publication Date: Nov 30, 2017
Pages: 5 - 018-0657-2
Sources ID: 40151
Notes: LR: 20180710; GR: 1R01CA181064/National Cancer Institute; GR: R01 CA181064/CA/NCI NIH HHS/United States; GR: K07 CA190529/CA/NCI NIH HHS/United States; GR: SUG1CA189961/National Cancer Institute; GR: R25 CA102618B/National Institutes of Health; GR: UG1 CA189961/CA/NCI NIH HHS/United States; GR: UG1CA189961/National Cancer Institute; GR: R25 CA102618/CA/NCI NIH HHS/United States; JID: 100888967; NIHMS951981; OTO: NOTNLM; 2018/02/02 06:00 [entrez]; 2018/02/02 06:00 [pubmed]; 2018/02/02 06:00 [medline]; epublish
Visibility: Public (group default)
Abstract: (Show)
PURPOSE OF REVIEW: To (1) explain what yoga is, (2) summarize published literature on the efficacy of yoga for managing cancer treatment-related toxicities, (3) provide clinical recommendations on the use of yoga for oncology professionals, and (4) suggest promising areas for future research. RECENT FINDINGS: Based on a total of 24 phase II and one phase III clinical trials, low-intensity forms of yoga, specifically gentle hatha and restorative, are feasible, safe, and effective for treating sleep disruption, cancer-related fatigue, cognitive impairment, psychosocial distress, and musculoskeletal symptoms in cancer patients receiving chemotherapy and radiation and cancer survivors. Clinicians should consider prescribing yoga for their patients suffering with these toxicities by referring them to qualified yoga professionals. More definitive phase III clinical trials are needed to confirm these findings and to investigate other types, doses, and delivery modes of yoga for treating cancer-related toxicities in patients and survivors.